Data from Exact Sciences' Clinical Trial Sends Stock Plunging | GenomeWeb

NEW YORK (GenomeWeb News) – Shares of Exact Sciences today fell as much as 30 percent after the company announced top-line data from a pivotal clinical trial for its colorectal cancer screening test.

Amid heavy trading, shares of the Madison, Wis.-based firm dipped to as low as $6.93 from Wednesday's closing price of $9.97, after results from the trial, called DeeP-C, failed to meet some internal targets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.